Literature DB >> 29302485

21-gene recurrence assay in patients receiving intraoperative radiotherapy: are "favorable" characteristics a surrogate for low recurrence?

Bridget A Oppong1, Surupa Sen Gupta1, Monique Gary1, Patricia Wehner2, Mihriye Mete3, Danjing Zhao2, Sulakshana Seevaratnam1, Sonali Rudra4, Shawna C Willey1.   

Abstract

BACKGROUND: Intraoperative radiotherapy (IORT) has gained momentum for early stage and favorable breast cancers (BC). The 21-gene recurrence assay guides treatment of hormone positive and node-negative BC.
METHODS: Analysis of 82 invasive BC treated with breast conservation surgery (BCS) and IORT 2013-2015. Data collection included patient demographics, tumor characteristics, nodal status, recurrence test (RS) and adjuvant therapy.
RESULTS: The mean age was 68 years. Tumors were stage Ia (86.6%), 3.6% Ib and 9.8% IIa. Of 50 patients (61.0%) with RS testing, 72% (n=36) were low risk (RS 0-17), with 28% (n=14) at intermediate risk (RS 18-30). The 39% (n=32) of patients without RS testing, were more likely to have smaller tumors (1.3 vs. 0.9 cm) and age >70 (P<0.05).
CONCLUSIONS: Most patients selected for IORT based on clinical features were indeed low risk based on RS. Given the limited long-term clinical outcome and safety data of this technique, additional investigation is needed.

Entities:  

Keywords:  21-gene recurrence score; Breast cancer (BC); accelerated partial breast radiation; intraoperative radiation therapy

Year:  2017        PMID: 29302485      PMCID: PMC5750322          DOI: 10.21037/gs.2017.07.05

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  22 in total

1.  Breast Cancer Version 2.2015.

Authors:  William J Gradishar; Benjamin O Anderson; Ron Balassanian; Sarah L Blair; Harold J Burstein; Amy Cyr; Anthony D Elias; William B Farrar; Andres Forero; Sharon Hermes Giordano; Matthew Goetz; Lori J Goldstein; Clifford A Hudis; Steven J Isakoff; P Kelly Marcom; Ingrid A Mayer; Beryl McCormick; Meena Moran; Sameer A Patel; Lori J Pierce; Elizabeth C Reed; Kilian E Salerno; Lee S Schwartzberg; Karen Lisa Smith; Mary Lou Smith; Hatem Soliman; George Somlo; Melinda Telli; John H Ward; Dorothy A Shead; Rashmi Kumar
Journal:  J Natl Compr Canc Netw       Date:  2015-04       Impact factor: 11.908

Review 2.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.

Authors:  M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

Review 3.  Evaluating the role of intra-operative radiation therapy in the modern management of breast cancer.

Authors:  M Barry; V Sacchini
Journal:  Surg Oncol       Date:  2012-08-11       Impact factor: 3.279

Review 4.  Intraoperative radiotherapy in early breast cancer.

Authors:  E Esposito; B Anninga; S Harris; I Capasso; M D'Aiuto; M Rinaldo; M Douek
Journal:  Br J Surg       Date:  2015-03-17       Impact factor: 6.939

5.  Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial.

Authors:  J A van Dongen; A C Voogd; I S Fentiman; C Legrand; R J Sylvester; D Tong; E van der Schueren; P A Helle; K van Zijl; H Bartelink
Journal:  J Natl Cancer Inst       Date:  2000-07-19       Impact factor: 13.506

Review 6.  American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

Authors:  Lyndsay Harris; Herbert Fritsche; Robert Mennel; Larry Norton; Peter Ravdin; Sheila Taube; Mark R Somerfield; Daniel F Hayes; Robert C Bast
Journal:  J Clin Oncol       Date:  2007-10-22       Impact factor: 44.544

7.  Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.

Authors:  Bernard Fisher; Stewart Anderson; John Bryant; Richard G Margolese; Melvin Deutsch; Edwin R Fisher; Jong-Hyeon Jeong; Norman Wolmark
Journal:  N Engl J Med       Date:  2002-10-17       Impact factor: 91.245

8.  Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer.

Authors:  Michael J Hassett; Samuel M Silver; Melissa E Hughes; Douglas W Blayney; Stephen B Edge; James G Herman; Clifford A Hudis; P Kelly Marcom; Jane E Pettinga; David Share; Richard Theriault; Yu-Ning Wong; Jonathan L Vandergrift; Joyce C Niland; Jane C Weeks
Journal:  J Clin Oncol       Date:  2012-05-14       Impact factor: 44.544

9.  The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.

Authors:  Joanne S Haviland; J Roger Owen; John A Dewar; Rajiv K Agrawal; Jane Barrett; Peter J Barrett-Lee; H Jane Dobbs; Penelope Hopwood; Pat A Lawton; Brian J Magee; Judith Mills; Sandra Simmons; Mark A Sydenham; Karen Venables; Judith M Bliss; John R Yarnold
Journal:  Lancet Oncol       Date:  2013-09-19       Impact factor: 41.316

10.  Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial.

Authors:  Jayant S Vaidya; Frederik Wenz; Max Bulsara; Jeffrey S Tobias; David J Joseph; Mohammed Keshtgar; Henrik L Flyger; Samuele Massarut; Michael Alvarado; Christobel Saunders; Wolfgang Eiermann; Marinos Metaxas; Elena Sperk; Marc Sütterlin; Douglas Brown; Laura Esserman; Mario Roncadin; Alastair Thompson; John A Dewar; Helle M R Holtveg; Steffi Pigorsch; Mary Falzon; Eleanor Harris; April Matthews; Chris Brew-Graves; Ingrid Potyka; Tammy Corica; Norman R Williams; Michael Baum
Journal:  Lancet       Date:  2013-11-11       Impact factor: 79.321

View more
  1 in total

1.  Oncotype testing in patients undergoing intraoperative radiation for breast cancer.

Authors:  Kelsey E Larson; Stephanie A Valente; Chirag Shah; Rahul D Tendulkar; Sheen Cherian; Jame Abraham; Courtney Yanda; Chao Tu; Jessica Echle; Stephen R Grobmyer
Journal:  Mol Clin Oncol       Date:  2018-08-23
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.